Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05038410
Other study ID # 2020CLI
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 30, 2021
Est. completion date October 5, 2022

Study information

Verified date October 2022
Source Mucos Pharma GmbH & Co. KG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the pharmacodynamic profile of an oral enzyme treatment with Bromelain, Trypsin and Rutoside in subjects with osteoarthritis.


Description:

This study is a randomised, placebo controlled, two parallel arms, cross over, and multicentric trial in 40 male and female subjects suffering from osteoarthritis. While is it well established that Wobenzyme is safe and have proven efficacy in painful conditions, inflammation and osteoarthritis, little is known about its clear mechanism of action underlying its clinical efficacy. This study hypothesises that oral enzyme combination therapy with Wobenzyme will lead to systemic pharmacodynamic effects which will be documented by a holistic assessment of the inflammasome, innate immune system, cartilage turnover, systemic inflammatory markers, as well as potential cellular pathways.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date October 5, 2022
Est. primary completion date October 5, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years to 100 Years
Eligibility Inclusion Criteria: 1. Male or female = 40 years of age and with BMI = 35 kg/m2; 2. Uni- or bilateral femorotibial knee OA : 1. Responding to clinical and radiological criteria of American College of Rheumatology (ACR); 2. Symptomatic for more than 6 months in the index knee; 3. Radiological Kellgren & Lawrence (K&L) grade II-III in standing x-rays from less than 12 months. 3. Mild-to-Moderate mean knee pain score at rest or at walking over the last 24 hours on the index knee evaluated on VAS (0-100) = 40 at baseline; 4. Able to follow the instructions of the study; 5. Having signed an informed consent. Exclusion Criteria: Related to knee: 1. Recent macro-trauma of the knee responsible of the symptomatic knee left to the Investigator's discretion; 2. Concurrent articular disease interfering with the evaluation of pain left to the Investigator's discretion; 3. Prosthesis in the target knee; 4. Knee swelling requiring corticosteroids local injection. Related to treatments: 5. Analgesics to manage knee pain 24 hours before inclusion visit; 6. Corticosteroids injection in the target knee in the last 3 months; 7. Hyaluronan injection in the target knee in the last 6 months; 8. Arthroscopy in the last 6 months; 9. Oral corticotherapy = 5mg/day (in Prednisolone equivalent) in the last 3 months; 10. Symptomatic slow-acting drugs for osteoarthritis (SYSADOA) or dietary supplement, i.e., curcuma extract, chondroitin, glucosamine, diacerein or avocado-soya unsaponifiables in the last 3 months; 11. An anticipated need for any forbidden treatments during the trial; 12. Contraindications to the product : 1. severe hepatic and renal impairment 2. congenital or acquired coagulation disorders, e.g. haemophilia 3. severe liver and/or kidney damage 4. hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption 13. Hypersensitivity or allergy to the product components, and pineapple; 14. Treatments based on strontium ranelate, bisphosphonates, selective estrogen-receptor modulator (SERM) and parathormone (PTH) in the last 12 months; 15. Treatment based on zoledronate in the last 2 years; 16. Treatment based on denosumab in the last 6 months; 17. Treatment with anticoagulants and/or anti-platelet agents Related to associated diseases: 18. Any severe, uncontrolled and limiting disease left to the Investigator's discretion; 19. Patient with widespread pain/depression (e.g. fibromyalgia); 20. Lower or upper extremity surgery or fracture in the last 6 months; 21. Anticipated need for any surgical or other invasive procedure during the trial including prosthesis in the target knee; 22. Severe alteration of mobility enabling functional evaluation. Related to subjects 23. Close collaborators to the investigational team, the study coordinator (ARTIALIS) or to the Sponsor; 24. Currently participating or having participated in another therapeutic clinical trial in the three previous months; 25. Having made a blood donation in the past month; 26. Under guardianship or judicial protection; 27. Pregnancy, breastfeeding, planned conception, or premenopausal women without effective contraception (tablet, patch, ring, diaphragm, implant and intrauterine device, tubal ligation or hysterectomy); 28. Counter-indication to an MRI examination.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Wobenzym®
Wobenzym®
Other:
Placebo
Microcrystalline cellulose

Locations

Country Name City State
Belgium Ziekenhuis Netwerk Antwerpen (ZNA) Middelheim Antwerpen
Belgium Centre Hospitalier Universitaire (CHU) Brugmann Bruxelles
Belgium Cliniques Universitaires Saint Luc UCL Bruxelles
Belgium UZ Brussel Jette
Belgium Centre Hospitalier Régional de la Citadelle Liège

Sponsors (3)

Lead Sponsor Collaborator
Mucos Pharma GmbH & Co. KG Artialis, Nestlé

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effects on cartilage biomarkers Change in sera biomarkers sColl2-1, sColl2-1NO2, sCOMP, sPIIANP and urine biomarker uCTXII between visit 0 and visit 5 measured using immunoassays (Enzyme-linked Immunosorbent assay, ELISA) 20 weeks
Primary Effects on markers of innate immune response Change in the expression of M1/M2 Polarization specific membrane markers on fresh blood macrophage, between visit 0 and visit 5 using flow cytometry 20 weeks
Primary Effects on systemic inflammatory markers Change in sera biomarkers NLRP 3 Inflammasome, a-2-macroglobulin, IL-1ß, TNFa, IL-6, IL-10, IL-4 between visit 0 and visit 5 measured using immunoassays (Enzyme-linked Immunosorbent assay, ELISA) 20 weeks
Primary Effects on cellular pathways Change in plasma proteomic profile using liquid chromatography-tandem mass spectrometry (LC-MS/MS) between visit 0 and visit 5. 20 weeks
Secondary Vital signs and anthropomorphic measurements Changes in systolic and diastolic Blood pressure (BP) in mmHg between visit -1 and visit 6 40 weeks
Secondary Vital signs and anthropomorphic measurements Changes in Heart Rate (HR) measured in beats per minute between visit -1 and visit 6 40 weeks
Secondary Vital signs and anthropomorphic measurements Changes in Temperature measured in degrees Celsius between visit -1 and visit 6 40 weeks
Secondary Vital signs and anthropomorphic measurements Changes in weight measured in kilograms, height measured in centimeters and BMI (weight and height will be combined to calculate BMI in kg/m2 between visit -1 and visit 6 40 weeks
Secondary Knee Pain Changes in knee pain at rest and while walking using a Visual Analogue Scale (1 to 100 mm scale where a higher score indicates greater pain intensity) between visit 0 and visit 6 36 weeks
Secondary Knee Function Changes in knee function using Knee injury and Osteoarthristis Outcome Score (KOOS). KOOS is a self-administrated questionnaire comprising 5 subscales: pains, symptoms, activities of daily living, sports and recreation function, and quality of life (0 to 100 scale where 100 indicates the best result) between visit 0 and visit 6 36 weeks
Secondary Patient global assessment of disease activity (PGADA) Changes in PGADA using a Visual Analogue Scale (1 to 100 mm scale where a higher score indicates a higher level of disease activity /a worse global health) between visit 0 and visit 6 36 weeks
Secondary Patient physical activity Effects on subject mobility using a connected device to record heart rate (beats/min between visit 0 and visit 6 36 weeks
Secondary Patient physical activity Effects on subject mobility using a connected device to record number of steps/day taken between visit 0 and visit 6 36 weeks
Secondary Patient physical activity Effects on subject mobility using a connected device to record number of climbed stairs/day between visit 0 and visit 6 36 weeks
Secondary Patient physical activity Effects on subject mobility using a connected device to record intensive exercise minutes/day between visit 0 and visit 6 36 weeks
Secondary Patient physical activity Effects on subject mobility using a connected device to record calories burned/day between visit 0 and visit 6minutes/day between visit 0 and visit 6 36 weeks
Secondary Body metabolism Effects on body metabolism marker TGF-ß1, TGF ß 2, TGF-ß 3 using immunoassays (Enzyme-linked Immunosorbent assay, ELISA) between visit 0 and visit 5 20 weeks
Secondary Clinical chemistry Number of participants with changes in clinical chemistry measurements (concentration of myostatin, hemoglobin, hematocrit, erythrocyte count, TG, TC, LDL, HDL, glucose, hsCRP, uric acid, coagulation markers and key hepatic enzymes) using immunoassays between visit 0 and visit 5 20 weeks
Secondary Joint structure modification Effects on joint structure using either MRI Osteoarthritis Knee Score (MOAKS - a semi quantitative scoring tool. Fourteen subregions are defined for scoring of articular cartilage and bone marrow lesions from grade 0 to grade 3. The more the grade increases, the more important the pathology) or Whole-Organ Magnetic Resonance Imaging Score (WORMS - a semi quantitative scoring tool that examines a spectrum of OA-related structural abnormalities including soft tissue, cartilage and bone in the knee at various anatomical subregion locations. The more the score increases, the more important the pathology) between visit 0 and visit 6 36 weeks
Secondary Volume of joint effusion Volume of joint effusion by MRI using volumetric segmentation method between visit 0 and visit 6 36 weeks
Secondary Tolerance Number of patients with Adverse Events, type of reported adverse events and subject drop out between visit -1 and visit 6 40 weeks
Secondary Compliance Tablet count of investigational product between visit 0 and visit 6 36 weeks
Secondary Responder rate to treatment Responder rate to treatment defined as changes in knee pain and/or knee function and/or patients disease activity using Pain and/or PGADA and/or KOOS according to recommendations of OMERACT OARSI (Osteoarthritis Research Society International (OARSI) Standing Committee for Clinical Trials Response Criteria Initiative and the Outcome Measures in Rheumatology (OMERACT), defined by either a high improvement in pain or in function >50% and absolute change >20 or an improvement in at least 2 of the 3 following: pain >20% and absolute change >10, function >20% and absolute change >10, patient's global assessment >20% and absolute change >10 (between visit 0 and visit 6 36 weeks
See also
  Status Clinical Trial Phase
Completed NCT04657926 - A Trial of APPA in the Treatment of Knee Osteoarthritis Phase 2
Completed NCT02536833 - A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects Phase 2
Completed NCT03014037 - Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration N/A
Recruiting NCT05937542 - A Qualitative Investigation of CLEAT Participants
Completed NCT03644615 - A Mindfulness Program (MBSR) in the Management of Symptomatic Hip and Knee Osteoarthritis N/A
Recruiting NCT06061367 - Muscles Strength and Gait Parameteres After TKA
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT03850665 - Comparison of Functional Outcome in Patients After Hip Arthroplasty Depending on Surgical Approach N/A
Completed NCT02826902 - Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial N/A
Completed NCT04402502 - Dynamic 4DCT to Examine Wrist Carpal Mechanics N/A
Completed NCT02923700 - Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial Phase 4
Recruiting NCT03167502 - Performance in Walking in Osteoarthritis Patients N/A
Completed NCT04564053 - Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants Phase 1
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Not yet recruiting NCT05036174 - Diphenhydramine Ointment for Knee Osteoarthritis N/A
Recruiting NCT02666443 - Low Dose Dexamethasone in Supraclavicular Blocks N/A
Recruiting NCT02912429 - Onlay vs. Inlay Patellofemoral Arthroplasty N/A
Active, not recruiting NCT02723929 - Effects of tDCS and tUS on Pain Perception in OA of the Knee
Withdrawn NCT02921594 - Kinematic Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties N/A